Hereditary Angioedema Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | KalVista Pharmaceuticals, Intellia Therapeutics, BioMarin Pharmaceutical, CSL Behring, Ionis Pharmaceuticals

DelveInsight's "Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hereditary Angioedema, historical and forecasted epidemiology as well as the Hereditary Angioedema market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Hereditary Angioedema market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hereditary Angioedema Market Forecast
https://www.delveinsight.com/sample-request/hereditary-angioedema-hae-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Hereditary Angioedema Market Report:
• The Hereditary Angioedema market size was valued approximately USD 2,147 million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• The number of diagnosed prevalent Hereditary Angioedema cases in the 7MM as a whole was 13,812 in 2021; this number is projected to rise by 2032 at a significant CAGR
• An estimated USD 347 million was taken in by the EU4, UK, and other nations in 2021; this amount is expected to increase by 2032
• In February 2021, The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) recently adopted a favourable opinion recommending the approval of ORLADEYO (Berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 and older. This was revealed by BioCryst Pharmaceuticals Inc.
• In February 2021, In its Phase 2 clinical trial for KVD900, an oral on-demand therapy for Hereditary Angioedema attacks, KalVista revealed encouraging findings.
• The UK had the largest diagnosed prevalent population of Hereditary Angioedema among the European nations in 2021 with 1,348 cases, followed by Germany with 1,266 cases. Spain and Italy, on the other hand, had the lowest and equal number of diagnosed prevalent cases (942 instances) in 2021
• Key Hereditary Angioedema Companies: KalVista Pharmaceuticals, Intellia Therapeutics, BioMarin Pharmaceutical, CSL Behring, Ionis Pharmaceuticals, Astria Therapeutics, Pharvaris Netherlands B.V, Takeda, Shire, Pharming Technologies B.V., BioCryst Pharmaceuticals, and others
• Key Hereditary Angioedema Therapies: KVD900, NTLA-2002, BMN 331, Garadacimab, Donidalorsen, STAR-0215, PHA121, TAK-743, Lanadelumab, rhC1INH, Berotralstat, and others
• The Hereditary Angioedema epidemiology based on gender analyzed that in the 7MM the diagnosed prevalent cases of Hereditary Angioedema varied according to gender, with prevalent cases higher in females than males
• The Hereditary Angioedema market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hereditary Angioedema pipeline products will significantly revolutionize the Hereditary Angioedema market dynamics.

Hereditary Angioedema Overview
Hereditary angioedema (HAE) is a rare hereditary disorder that typically affects the skin, intestines, upper respiratory system, and oropharynx. It appears as recurrent episodes of localised subcutaneous (SC) or mucosal edoema.

Get a Free sample for the Hereditary Angioedema Market Report
https://www.delveinsight.com/report-store/hereditary-angioedema-hae-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hereditary Angioedema Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hereditary Angioedema Epidemiology Segmentation:
The Hereditary Angioedema market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Hereditary Angioedema
• Prevalent Cases of Hereditary Angioedema by severity
• Gender-specific Prevalence of Hereditary Angioedema
• Diagnosed Cases of Episodic and Chronic Hereditary Angioedema

Download the report to understand which factors are driving Hereditary Angioedema epidemiology trends @ Hereditary Angioedema Epidemiology Forecast
https://www.delveinsight.com/sample-request/hereditary-angioedema-hae-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hereditary Angioedema Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hereditary Angioedema market or expected to get launched during the study period. The analysis covers Hereditary Angioedema market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Hereditary Angioedema Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hereditary Angioedema Therapies and Key Companies
• KVD900: KalVista Pharmaceuticals
• NTLA-2002: Intellia Therapeutics
• BMN 331: BioMarin Pharmaceutical
• Garadacimab: CSL Behring
• Donidalorsen: Ionis Pharmaceuticals
• STAR-0215: Astria Therapeutics
• PHA121: Pharvaris Netherlands B.V
• TAK-743: Takeda
• Lanadelumab: Shire
• rhC1INH: Pharming Technologies B.V.
• Berotralstat: BioCryst Pharmaceuticals

Discover more about therapies set to grab major Hereditary Angioedema market share @ Hereditary Angioedema Treatment Market
https://www.delveinsight.com/sample-request/hereditary-angioedema-hae-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hereditary Angioedema Market Strengths
• Increasing identification of a novel genetic mutation in various regions warranting further focus on the types and associated pathophysiology, including recognition of hormonal changes

Hereditary Angioedema Market Opportunities
• Proliferating demand for therapies with improved patient compliance, fewer side effects, improved resistance profile, and long-acting therapies

Scope of the Hereditary Angioedema Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Hereditary Angioedema Companies: KalVista Pharmaceuticals, Intellia Therapeutics, BioMarin Pharmaceutical, CSL Behring, Ionis Pharmaceuticals, Astria Therapeutics, Pharvaris Netherlands B.V, Takeda, Shire, Pharming Technologies B.V., BioCryst Pharmaceuticals, and others
• Key Hereditary Angioedema Therapies: KVD900, NTLA-2002, BMN 331, Garadacimab, Donidalorsen, STAR-0215, PHA121, TAK-743, Lanadelumab, rhC1INH, Berotralstat, and others
• Hereditary Angioedema Therapeutic Assessment: Hereditary Angioedema current marketed and Hereditary Angioedema emerging therapies
• Hereditary Angioedema Market Dynamics: Hereditary Angioedema market drivers and Hereditary Angioedema market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Hereditary Angioedema Unmet Needs, KOL's views, Analyst's views, Hereditary Angioedema Market Access and Reimbursement

To know more about Hereditary Angioedema companies working in the treatment market, visit @ Hereditary Angioedema Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/hereditary-angioedema-hae-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Hereditary Angioedema Market Report Introduction
2. Executive Summary for Hereditary Angioedema
3. SWOT analysis of Hereditary Angioedema
4. Hereditary Angioedema Patient Share (%) Overview at a Glance
5. Hereditary Angioedema Market Overview at a Glance
6. Hereditary Angioedema Disease Background and Overview
7. Hereditary Angioedema Epidemiology and Patient Population
8. Country-Specific Patient Population of Hereditary Angioedema
9. Hereditary Angioedema Current Treatment and Medical Practices
10. Hereditary Angioedema Unmet Needs
11. Hereditary Angioedema Emerging Therapies
12. Hereditary Angioedema Market Outlook
13. Country-Wise Hereditary Angioedema Market Analysis (2019-2032)
14. Hereditary Angioedema Market Access and Reimbursement of Therapies
15. Hereditary Angioedema Market Drivers
16. Hereditary Angioedema Market Barriers
17. Hereditary Angioedema Appendix
18. Hereditary Angioedema Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Hereditary Angioedema Pipeline https://www.delveinsight.com/report-store/hereditary-angioedema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Hereditary Angioedema Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Hereditary Angioedema market. A detailed picture of the Hereditary Angioedema pipeline landscape is provided, which includes the disease overview and Hereditary Angioedema treatment guidelines.
Hereditary Angioedema Epidemiology https://www.delveinsight.com/report-store/hereditary-angioedema-hae-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Hereditary Angioedema Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Hereditary Angioedema epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.